takeda.com
U.S. FDA Accepts Takeda sBLA for Review in Pediatric UC and Crohn's Disease
This could expand an approved, gut-targeted biologic (vedolizumab/ENTYVIO) to children as young as 2 with UC or Crohn’s disease, addressing a pediatric treatment gap if the FDA approves the sBLA. Families and clinicians seeking additional pediatric biologic options may be affected.
Pediatric patients with moderately to severely active UC or Crohn’s disease and their families; clinicians who treat pediatric IBD; researchers and others following pediatric IBD drug development.
What To Know
Takeda announced the U.S. FDA has accepted its supplemental biologics license application (sBLA) to expand intravenous ENTYVIO (vedolizumab) use to pediatric patients ages 2 and older with moderately to severely active ulcerative colitis and Crohn’s disease.
The company says the submission is supported by two Phase 3 pediatric trials (KEPLER in UC and WEBB in Crohn’s), and the FDA set a PDUFA goal date in early 2027.
ENTYVIO is described in the release as a gut-focused anti-α4β7 integrin biologic currently approved for adults; Takeda highlights prior adult data and pediatric trial designs but does not report new pediatric efficacy or safety results in this announcement. The release also notes parallel regulatory submissions in Europe and plans for additional markets.
If approved, Takeda states ENTYVIO IV would become an option for children two years and older. The company includes standard safety and contraindication information in the release, and references trial identifiers for those who want to look up details on ClinicalTrials.gov.
This is a regulatory update announcing FDA acceptance of an application and a PDUFA target date; the release refers to Phase 3 pediatric trials but does not present trial results or new safety data. Approval is not guaranteed, and treatment availability will depend on regulatory review and labeling decisions.
